utic Potential of Stem Cells in Neurodegenerative Diseases

69

-H. Xie, Z. Liu, X.-R. Zhang, et al., “Wharton’s jelly-derived mes-

chymal stem cells alleviate memory deficits and reduce amyloid-β

position in an app/ps1 transgenic mouse model,” Clinical and Ex-

rimental Medicine, vol. 16, pp. 89–98, 2 2016.

Fang, T. Gao, B. Zhang, et al., “Recent advances: Decoding

zheimer’s disease with stem cells,” Frontiers in Aging Neuroscience,

l. 10, 3 2018.

Srivastava, A. Li, T. Datta, et al., “Advances in stromal cell ther-

y for management of alzheimer’s disease,” Frontiers in Pharmacology,

l. 13, 10 2022.

Chen, S. Jiang, R. Wang, et al., “Neural stem cells in the treatment

alzheimer’s disease: Current status, challenges, and future prospects,”

urnal of Alzheimer’s Disease, vol. 94, pp. S173–S186, 7 2023.

Hayashi, H.-T. Lin, C.-C. Lee, et al., “Effects of neural stem cell

ansplantation in alzheimer’s disease models,” Journal of Biomedical

ience, vol. 27, p. 29, 12 2020.

Zhou, B. Shi, Y. Xu, et al., “Neural stem/progenitor cell therapy for

zheimer disease in preclinical rodent models: a systematic review and

eta-analysis,” Stem Cell Research and Therapy, vol. 14, p. 3, 1 2023.

. Mamelak, “Parkinson’s disease, the dopaminergic neuron and

mmahydroxybutyrate,” Neurology and Therapy, vol. 7, pp. 5–11, 6

18.

N. Alerte, A. A. Akinfolarin, E. E. Friedrich, et al., “α-synuclein ag-

egation alters tyrosine hydroxylase phosphorylation and immunoreac-

vity: Lessons from viral transduction of knockout mice,” Neuroscience

tters, vol. 435, pp. 24–29, 4 2008.

. Funayama, K. Nishioka, Y. Li, et al., “Molecular genetics of parkin-

n’s disease: Contributions and global trends,” Journal of Human Ge-

tics, vol. 68, pp. 125–130, 3 2023.

Ferrari, A. Cardinale, B. Picconi, et al., “From cell lines to pluripotent

em cells for modelling parkinson’s disease,” Journal of Neuroscience

ethods, vol. 340, p. 108741, 7 2020.

Soldner, J. Laganière, A. W. Cheng, et al., “Generation of isogenic

uripotent stem cells differing exclusively at two early onset parkinson

int mutations,” Cell, vol. 146, pp. 318–331, 7 2011.

Fernández‐Santiago, I. Carballo‐Carbajal, G. Castellano, et al.,

Aberrant epigenome in ipsc‐derived dopaminergic neurons from parkin-

n’s disease patients,” EMBO Molecular Medicine, vol. 7, pp. 1529–

46, 12 2015.